# Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

> **NCT01849250** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 65 (actual)

## Conditions studied

- Benign Breast Neoplasm
- Ductal Breast Carcinoma In Situ
- Invasive Breast Carcinoma
- Lobular Breast Carcinoma In Situ
- Paget Disease of the Breast
- Stage IA Breast Cancer
- Stage IB Breast Cancer
- Stage IIA Breast Cancer
- Stage IIB Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer

## Interventions

- **DRUG:** Docosahexaenoic Acid
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01849250
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2016-01-11
- **Final completion:** 2020-04-22
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2021-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01849250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01849250, "Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01849250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*